NCT07529249

Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women

Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women With Dry Skin

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Centre de Pharmacologie Clinique Applique a la Dermatologie · Academic / Other
• Sex: Female
• Age: 45 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.

Detailed description

This study is designed to evaluate whether daily supplementation with collagen-derived peptides can improve the skin barrier of the face in women who have dry and sensitive skin. Participants will receive one of two different concentrations of collagen-derived peptides or a placebo, and the effects will be assessed after three months of treatment. The main goal is to compare the two active supplement doses against placebo to see if collagen peptides help strengthen or restore skin barrier integrity. The secondary objectives are to assess the impact of both concentrations on: * skin barrier integrity at two anatomical sites (face and leg) at T1, T2 and T3 (Tewameter®); * skin hydration at two anatomical sites (face and leg) at T1, T2 and T3 (Corneometer®); * skin barrier resistance (leg) after 10 strippings at T2 and T3 (Tewameter®); * skin barrier permeability (leg) at T2 and T3 (Caffeine penetration assay); * skin elasticity at two anatomical sites (face and leg) at T1, T2 and T3 (Cutometer®); * skin pH (face) at T1, T2 and T3 (pH-Meter®); * crow's feet wrinkles and fine lines at T1, T2 and T3 (PRIMOS®); * dermal thickness (Face) at T1, T2 and T3 (Dermscan®); * clinical signs (dryness, roughness, redness) at T1, T2 and T3 (clinical assessments); * subjective symptoms (tightness, itching, burning sensation) at T1, T2 and T3 (subject evaluation); * ceramide levels and other skin lipids (leg) at T2 and T3 (D-squame®); * ceramide levels and other skin lipids (face) at T3 (D-squame®); * participant perceived efficacy (Self-assessment questionnaire) at T1, T2 and T3; * safety at an ongoing basis (Adverse Event reporting).

Conditions

• Dry Skin
• Sensitive Skin
• Dry Skin in the Elderly
• Dietary Supplement

Interventions

Type	Name	Description
DRUG	Investigational Product 1	This product is going to be concentrated at 2000mg
DRUG	Investigational Product 2	This product is going to be concentrated at 5000mg
DIETARY_SUPPLEMENT	Placebo	This product is going to be flavoured water

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-08-01
• Completion: 2026-09-01
• First posted: 2026-04-14
• Last updated: 2026-04-14

Locations

1 site across 1 country: France